Literature DB >> 3756089

Operation manual for control of production, preclinical toxicology and phase I trials of anti-tumour antibodies and drug antibody conjugates. Prepared by a Joint Committee of the: Cancer Research Campaign National Institute for Biological Standards and Control.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3756089      PMCID: PMC2001634          DOI: 10.1038/bjc.1986.209

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  2 in total

1.  Predicting anticancer drug effects in man from laboratory animal studies.

Authors:  A H OWENS
Journal:  J Chronic Dis       Date:  1962-03

2.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05
  2 in total
  4 in total

1.  Of mice and men...

Authors:  A C Perkins
Journal:  Eur J Nucl Med       Date:  1992

2.  Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.

Authors:  A P Zbar; H Thomas; R W Wilkinson; M Wadhwa; K N Syrigos; E L Ross; P Dilger; T G Allen-Mersh; W A Kmiot; A A Epenetos; D Snary; W F Bodmer
Journal:  Int J Colorectal Dis       Date:  2005-04-30       Impact factor: 2.571

3.  Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients.

Authors:  E O Aboagye; S K Luthra; F Brady; K Poole; H Anderson; T Jones; A Boobis; S S Burtles; P Price
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

4.  Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study.

Authors:  J L Casey; M P Napier; D J King; R B Pedley; L C Chaplin; N Weir; L Skelton; A J Green; L D Hope-Stone; G T Yarranton; R H J Begent
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.